Equity · Healthcare
XENE
Xenon Pharmaceuticals Inc. · NasdaqGM
The line runs $54.67 on 20 May through $68 on 17 July, on a scale from $50 to $80. Days the market did not trade hold the previous close, flat.
The chart above plots the price of XENE over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $54.67 on 20 May 2026 through $68 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026
XENE insider trades
XENE has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 8 December 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
XENE reported financials
XENE reported revenue of $7.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$345.9M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
XENE earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
XENE institutional holders
13 of the 45 institutional funds we track reported a XENE position for the quarter ended 30 Jun 2026 — a combined $381.3M; the latest of those filings landed 14 Aug 2026.
Showing the 10 largest of 13 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
XENE fails-to-deliver
On 31 Jul 2026, 322 shares of XENE failed to deliver (about $21K).
Source: SEC fails-to-deliver (CNS) data